智通财经APP讯，复锐医疗科技(01696)发布公告，旗下获再授权注射用A型肉毒毒素(DaxibotulinumtoxinA-lanm，中国境内商标达希斐®，英文商标DAXXIFY®，项目代号RT002，以下简称“达希斐”)已通过中国食品药品检定研究院质量标准检验。该产品适用于暂时性改善成人因皱眉肌和╱或降眉间肌活动引起的中度至重度眉间纹。
截至本公告发布之日，于中国境内尚无DaxibotulinumtoxinA型肉毒毒素产品上市销售。此次检验通过标志着达希斐已满足中国国家药品监管部门对质量、安全与有效性的严格要求。目前，公司已达成达希斐于中国市场的首批商业订单合作，正式迈入商业化实施阶段。
公司相信，达希斐作为公司注射填充业务的战略基石，将通过丰富公司产品组合的多样性，为求美者提供更多优质选择，并将作为第二增长引擎，为公司带来持续性耗材收入，巩固公司在全球美丽健康行业的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.